Morgan Stanley lowered the firm’s price target on Acadia Pharmaceuticals to $30 from $40 and keeps an Overweight rating on the shares. Following yesterday afternoon’s pimavanserin Phase 3 release for negative symptoms of schizophrenia, or NSS, the firm updated its model by removing pimavanserin in NSS and adding Daybue in geographies including Canada, Japan, and Europe starting in 2025 as Acadia is preparing for launches outside the U.S.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACAD:
- Acadia Pharmaceuticals price target lowered to $19 from $25 at Oppenheimer
- Acadia Pharmaceuticals price target lowered to $31 from $40 at Baird
- Acadia Pharmaceuticals price target lowered to $30 from $33 at BofA
- Acadia Pharmaceuticals price target lowered to $33 from $40 at Canaccord
- Acadia Pharmaceuticals price target lowered to $39 from $44 at JMP Securities
